Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Sep 15, 2021; 13(9): 1184-1195
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.1184
Published online Sep 15, 2021. doi: 10.4251/wjgo.v13.i9.1184
Variable | Distal non-diffuse type | Proximal non-diffuse type | Diffuse type |
Gender (%) | |||
Male | 416 (63.6) | 324 (70.0) | 848 (53.0) |
Female | 238 (36.4) | 139 (30.0) | 753 (47.0) |
Age (%) | |||
< 60 yr | 200 (30.6) | 167 (36.1) | 850 (53.1) |
≥ 60 yr | 454 (69.4) | 296 (63.9) | 751 (46.9) |
Tumor size (%) | |||
< 4.0 cm | 318 (48.6) | 218 (47.1) | 664 (41.5) |
≥ 4.0 cm | 310 (47.4) | 221 (47.7) | 771 (48.2) |
Unknown | 26 (4.0) | 24 (5.2) | 166 (10.4) |
Retrieved lymph nodes (%) | |||
Adequate (n ≥ 16) | 326 (49.8) | 261 (56.4) | 831 (51.9) |
Inadequate (n < 16) | 328 (50.2) | 202 (43.6) | 770 (48.1) |
AJCC 8th pT stage (%) | |||
pT1 | 211 (32.3) | 123 (26.6) | 356 (22.2) |
pT2 | 87 (13.3) | 69 (14.9) | 173 (10.8) |
pT3 | 207 (31.7) | 149 (32.2) | 464 (29.0) |
pT4a | 101 (15.4) | 89 (19.2) | 480 (30.0) |
pT4b | 48 (7.3) | 33 (7.1) | 128 (8.0) |
AJCC 8th pN stage (%) | |||
pN0 | 302 (46.2) | 197 (42.5) | 532 (33.2) |
pN1 | 117 (17.9) | 79 (17.1) | 260 (16.2) |
pN2 | 115 (17.6) | 90 (19.4) | 302 (18.9) |
pN3a | 95 (14.5) | 70 (15.1) | 347 (21.7) |
pN3b | 25 (3.8) | 27 (5.8) | 160 (10.0) |
Differentiation grade (%) | |||
Well differentiation | 66 (10.1) | 26 (5.6) | 3 (0.2) |
Moderate differentiation | 269 (41.1) | 170 (36.7) | 44 (2.7) |
Poor differentiation | 311 (47.6) | 259 (55.9) | 1484 (92.7) |
Undifferentiation | 8 (1.2) | 8 (1.7) | 70 (4.4) |
Variable | No. of patients (%) | Univariate analysis | Multivariate analysis | ||
5-yr OS | P value | HR (95%CI) | P value | ||
Gender (%) | 0.111 | ||||
Male | 1588 (58.4) | 45.9% | |||
Female | 1130 (41.6) | 49.1% | |||
Age (%) | < 0.001 | < 0.001 | |||
< 60 yr | 1217 (44.8) | 50.7% | 1 (Ref) | – | |
≥ 60 yr | 1501 (55.2) | 44.4% | 1.157 (1.360–1.692) | < 0.001 | |
Tumor size (%) | < 0.001 | 0.001 | |||
≤ 4.0 cm | 1200 (44.2) | 63.9% | 1 (Ref) | – | |
> 4.0 cm | 1302 (47.9) | 33.6% | 1.179 (1.038–1.339) | 0.011 | |
Unknown | 216 (7.9) | 40.2% | 1.457 (1.191–1.782) | < 0.001 | |
Retrieved lymph nodes (%) | 0.074 | < 0.001 | |||
Adequate (n ≥ 16) | 1418 (52.2) | 48.9% | 1 (Ref) | – | |
Inadequate (n < 16) | 1300 (47.8) | 45.5% | 1.550 (1.380–1.740) | < 0.001 | |
AJCC 8th pT stage (%) | < 0.001 | < 0.001 | |||
pT1 | 690 (25.4) | 80.9% | 1 (Ref) | – | |
pT2 | 329 (12.1) | 66.6% | 1.535 (1.193–1.975) | 0.001 | |
pT3 | 820 (30.2) | 38.5% | 2.882 (2.334–3.558) | < 0.001 | |
pT4a | 670 (24.7) | 23.4% | 3.415 (2.740–4.256) | < 0.001 | |
pT4b | 209 (7.7) | 18.6% | 4.452 (3.458–5.732) | < 0.001 | |
AJCC 8th pN stage (%) | < 0.001 | < 0.001 | |||
pN0 | 1031 (37.9) | 71.6% | 1 (Ref) | – | |
pN1 | 456 (16.8) | 46.9% | 1.467 (1.225–1.757) | < 0.001 | |
pN2 | 507 (18.7) | 37.5% | 1.611 (1.353–1.919) | < 0.001 | |
pN3a | 512 (18.8) | 24.8% | 2.356 (1.976–2.809) | < 0.001 | |
pN3b | 212 (7.8) | 9.2% | 4.138 (3.306–5.181) | < 0.001 | |
Differentiation grade (%) | 0.011 | 0.135 | |||
Well differentiation | 95 (3.5) | 69.4% | 1 (Ref) | – | |
Moderate differentiation | 483 (17.8) | 58.9% | 0.974 (0.649–1.462) | 0.898 | |
Poor differentiation | 2054 (75.5) | 44.0% | 1.123 (0.755–1.670) | 0.566 | |
Undifferentiation | 86 (3.2) | 35.6% | 1.415 (0.876–2.285) | 0.156 | |
Modified Lauren classification (%) | < 0.001 | 0.013 | |||
Distal non-diffuse type | 654 (24.1) | 58.8% | 1 (Ref) | – | |
Proximal non-diffuse type | 463 (17.0) | 48.3% | 1.230 (1.033–1.466) | 0.020 | |
Diffuse type | 1601 (58.9) | 42.4% | 1.246 (1.068–1.452) | 0.005 |
Pathological classification/prognostic model | AUC (95%CI) | AIC | |
3-yr overall survival | 5-yr overall survival | ||
Differentiation grade | 0.626 (0.608–0.644) | 0.621 (0.602–0.639) | 25971 |
Lauren classification | 0.666 (0.647–0.683) | 0.681 (0.663–0.699) | 25923 |
Modified Lauren classification | 0.679 (0.661–0.696) | 0.702 (0.685–0.719) | 25877 |
DeLong tests for AUCs | |||
Differentiation grade vs Lauren | P < 0.001 | P < 0.001 | – |
Lauren vs modified Lauren | P < 0.001 | P < 0.001 | – |
Modified Lauren vs differentiation grade | P < 0.001 | P < 0.001 | – |
Novel prognostic model | 0.803 (0.786–0.819) | 0.804 (0.787–0.820) | 20010 |
Age, tumor size, retrieved lymph nodes, pT stage, pN stage, modified Lauren classification | |||
Control model | 0.776 (0.759–0.793) | 0.776 (0.759–0.793) | 20144 |
AJCC 8th pTNM stage (pT stage, pN stage) |
- Citation: Ning FL, Zhang NN, Wang J, Jin YF, Quan HG, Pei JP, Zhao Y, Zeng XT, Abe M, Zhang CD. Prognostic value of modified Lauren classification in gastric cancer. World J Gastrointest Oncol 2021; 13(9): 1184-1195
- URL: https://www.wjgnet.com/1948-5204/full/v13/i9/1184.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i9.1184